Skip to main content

Generic Perforomist Availability

Last updated on Nov 9, 2021.

Perforomist is a brand name of formoterol, approved by the FDA in the following formulation(s):

PERFOROMIST (formoterol fumarate - solution;inhalation)

  • Manufacturer: MYLAN SPECLT
    Approval date: May 11, 2007
    Strength(s): 0.02MG/2ML [RLD] [AN]

Has a generic version of Perforomist been approved?

A generic version of Perforomist has been approved by the FDA. However, this does not mean that the product will necessarily be commercially available - possibly because of drug patents and/or drug exclusivity. The following products are equivalent to Perforomist and have been approved by the FDA:

formoterol fumarate solution;inhalation

  • Manufacturer: TEVA PHARMS USA INC
    Approval date: June 22, 2021
    Strength(s): 0.02MG/2ML [AN]

Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Perforomist. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

See also: Generic Drug FAQ.

Related Patents

Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.

  • Bronchodilating compositions and methods
    Patent 6,667,344
    Issued: December 23, 2003
    Inventor(s): Partha S.; Banerjee & Stephen; Pham & Samuel O.; Akapo & Imtiaz A.; Chaudry
    Assignee(s): Dey, L.P.

    Bronchodilating compositions and methods are provided. The compositions are intended for administration as a nebulized aerosol. In certain embodiments, the compositions contain formoterol, or a derivative thereof. Methods for treatment, prevention, or amelioration of one or more symptoms of bronchoconstrictive disorders using the compositions provided herein are also provided.

    Patent expiration dates:

    • June 22, 2021
      ✓ 
      Drug product
  • Bronchodilating compositions and methods
    Patent 6,814,953
    Issued: November 9, 2004
    Inventor(s): Partha S.; Banerjee & Stephen; Pham & Samuel O.; Akapo & Imtiaz A.; Chaudry
    Assignee(s): Dey L.P.

    Bronchodilating compositions and methods are provided. The compositions are intended for administration as a nebulized aerosol. In certain embodiments, the compositions contain formoterol, or a derivative thereof. Methods for treatment, prevention, or amelioration of one or more symptoms of bronchoconstrictive disorders using the compositions provided herein are also provided.

    Patent expiration dates:

    • June 22, 2021
      ✓ 
      Patent use: MAINTENANCE TREATMENT OF BRONCHOCONSTRICTION IN PATIENTS WITH CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD)
      ✓ 
      Drug product
  • Bronchodilating β-agonist compositions and methods
    Patent 7,348,362
    Issued: March 25, 2008
    Inventor(s): Banerjee; Partha S. & Chaudry; Imtiaz A. & Pham; Stephen
    Assignee(s): Dey, L.P.

    Bronchodilating compositions and methods are provided. The compositions are intended for administration as a nebulized aerosol. In certain embodiments, the compositions contain formoterol, or a derivative thereof. Methods for treatment, prevention, or amelioration of one or more symptoms of bronchoconstrictive disorders using the compositions provided herein are also provided.

    Patent expiration dates:

    • June 22, 2021
      ✓ 
      Drug product
  • Bronchodilating beta-agonist compositions and methods
    Patent 7,462,645
    Issued: December 9, 2008
    Inventor(s): Chaudry; Imtiaz A. & Pham; Stephen & Banerjee; Partha S.
    Assignee(s): JPMorgan Chase Bank, N.A.

    Bronchodilating compositions and methods are provided. The compositions are intended for administration as a nebulized aerosol. In certain embodiments, the compositions contain formoterol, or a derivative thereof. Methods for treatment, prevention, or amelioration of one or more symptoms of bronchoconstrictive disorders using the compositions provided herein are also provided.

    Patent expiration dates:

    • June 22, 2021
      ✓ 
      Patent use: MAINTENANCE TREATMENT OF BRONCHOCONSTRICTION IN PATIENTS WITH CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD)
      ✓ 
      Drug product
  • Bronchodilating Beta-agonist compositions and methods
    Patent 8,623,922
    Issued: January 7, 2014
    Assignee(s): Dey Pharma, L.P.

    Bronchodilating compositions and methods are provided. The compositions are intended for administration as a nebulized aerosol. In certain embodiments, the compositions contain formoterol, or a derivative thereof. Methods for treatment, prevention, or amelioration of one or more symptoms of bronchoconstrictive disorders using the compositions provided herein are also provided.

    Patent expiration dates:

    • June 22, 2021
      ✓ 
      Drug product
  • Bronchodilating beta-agonist compositions and methods
    Patent 9,730,890
    Issued: August 15, 2017
    Assignee(s): Mylan Pharmaceuticals, Inc.

    Bronchodilating compositions and methods are provided. The compositions are intended for administration as a nebulized aerosol. In certain embodiments, the compositions contain formoterol, or a derivative thereof. Methods for treatment, prevention, or amelioration of one or more symptoms of bronchoconstrictive disorders using the compositions provided herein are also provided.

    Patent expiration dates:

    • June 22, 2021
      ✓ 
      Drug product

Glossary

Term Definition
Drug Patent A drug patent is assigned by the U.S. Patent and Trademark Office and assigns exclusive legal right to the patent holder to protect the proprietary chemical formulation. The patent assigns exclusive legal right to the inventor or patent holder, and may include entities such as the drug brand name, trademark, product dosage form, ingredient formulation, or manufacturing process A patent usually expires 20 years from the date of filing, but can be variable based on many factors, including development of new formulations of the original chemical, and patent infringement litigation.
Drug Exclusivity Exclusivity is the sole marketing rights granted by the FDA to a manufacturer upon the approval of a drug and may run simultaneously with a patent. Exclusivity periods can run from 180 days to seven years depending upon the circumstance of the exclusivity grant.
RLD A Reference Listed Drug (RLD) is an approved drug product to which new generic versions are compared to show that they are bioequivalent. A drug company seeking approval to market a generic equivalent must refer to the Reference Listed Drug in its Abbreviated New Drug Application (ANDA). By designating a single reference listed drug as the standard to which all generic versions must be shown to be bioequivalent, FDA hopes to avoid possible significant variations among generic drugs and their brand name counterpart.
AN Solutions and powders for aerosolization. Uncertainty regarding the therapeutic equivalence of aerosolized products arises primarily because of differences in the drug delivery system. Solutions and powders intended for aerosolization that are marketed for use in any of several delivery systems are considered to be pharmaceutically and therapeutically equivalent and are coded AN. Those products that are compatible only with a specific delivery system or those products that are packaged in and with a specific delivery system are coded BN, unless they have met an appropriate bioequivalence standard. Solutions or suspensions in a specific delivery system will be coded AN if the bioequivalence standard is based upon in vitro methodology, if bioequivalence needs to be demonstrated by in vivo methodology then the drug products will be coded AB.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.